The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of survivalbenefitandtolerability.Inaddition,therearefewstudiesspecificallydesignedforpatientsover65years.Subsetanalysesof individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.
Introduction
As our population ages, the treatment of older patients with cancer will become a more common part of oncology practice. Unfortunately, the geriatric population has typically been underrepresented in clinical trials, representing only 25%-30% of study participants. 1, 2 As a result, it is unclear if many of the advances in cancer treatment also apply to the elderly.
Data on studies in colorectal cancer indicate physicians are often reluctant to give elderly patients chemotherapy or to enroll them in clinical trials. 3, 4 Even after adjusting for comorbidities, performance status, and other treatment predictors, elderly patients are less likely to receive chemotherapy. 4 If they do receive palliative or adjuvant chemotherapy, it is often at reduced doses and/or with fewer cycles of treatment. This may affect outcomes, as data from the Surveillance,Epidemiology,andEndResults(SEER) database suggest elderly patients who receive longer durations of 5-FU based chemotherapy have reduced mortality. 5 There is also evidence that among patients with comorbidities, those who receive cancer treatment survive longer. 6 Many investigators have attempted to address the gap that exists between the treatment of younger and older patients with cancer. This review focuses on the available data regarding systemic therapy for elderly patients with gastrointestinal malignancies, including colorectal, pancreatic, and gastroesophageal cancers.
colorectal cancer
Colorectal cancer (CRC) is the third most common cancer for both men and women, with 150,000 new diagnoses each year and 50,000 deaths per year. 7 The incidence of colorectal cancer increases with each decade of life. The median age at diagnosis is 71 years, and patients $65 years of age comprise 67% all colorectal cancer diagnoses. 8, 9 While the data are fairly consistent for older patients with metastatic CRC(mCRC),whetherelderlypatientsbenefitfrom recent advances in the adjuvant setting remains an area of controversy.
Adjuvant therapy
The prior standard of care for adjuvant therapy for colorectal cancer was 5-fluorouracil combined with leucovorin(5-FU/LV).Thebenefitofadjuvant5-FU therapy in elderly patients is clear. Three retrospective analyses documented improved survival with the use of adjuvant 5-FU therapy compared with surgery alone. [10] [11] [12] Itisnotasevidentifelderlypatientsbenefitfrom the new standards in adjuvant therapy. Clinical trials have demonstrated that the addition of the chemotherapeuticagentoxaliplatinsignificantlyimproved outcomes for patients with stage III colon cancer over 5-FU/LV alone. Oxaliplatin plus 5-FU/LV (or capecitabine) in the adjuvant setting improves 3-year disease-free survival (DFS) [13] [14] [15] and overall survival(OS). 13 Thus, the combination of oxaliplatin and 5-FU/LV (or capecitabine) has become the standardofcareintheadjuvantsettingforstageIII disease.
Due to the lack of randomized trials aimed specifically at the elderly, much of the data on the use of oxaliplatin in the elderly comes from subset analyses of large randomized trials or pooled analyses involving multiple trials. One of the most detailed retrospective analyses evaluating oxaliplatin use in the elderly was a pooled analysis of 1,567 patients $70 years from clinical trials undergoing treatment with 5-FU/LV/oxaliplatin (FOLFOX) in either the adjuvant or advanced setting. 16 Toxicities were fairly similar between older and younger patients, with the exception of neutropenia and thrombocytopeniabeingsignificantlyhigherinpatients$70 years. Additionally, the mortality at 60 days from starting therapy was not significantly different between young and older patients (1.1% vs. 2.3%, P = 0.2). Neither DFS nor OS differed significantly between patients ,70 years and those $70years.Onmultivariate analysis, age was not associated with likelihood of response among patients in the advanced disease trials. Dose intensity did not differ between older and younger patients, although older patients did receive fewer cycles of therapy.
The results from this pooled analysis suggest that oxaliplatin-based therapy can be administered with onlymildlyincreasedtoxicity.Thedataalsoconfirm thatelderlypatientscanbenefitfromthesetherapies similarlytoyoungerpatientsintermsofDFSandOS. However, the majority of the patients in this study weretreatedintheadvancedsetting.Inaddition,all Europeantrials,whichmadeupasignificantpercentage of the patients in the pooled analysis, did not include patients over the age of 75.
Studiesofpatientsreceivingtherapypurelyinthe adjuvantsettinghaveledtoconflictingdataregarding thebenefitofoxaliplatininelderly.Subsetanalysesof theMulticenterInternationalStudyofOxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) and the National SurgicalAdjuvant Breast and Bowel Project (NASBP) C-07trialsdemonstratedthatthebenefitofadjuvant oxaliplatin-based therapy for elderly patients is not statistically significant. 13, 15 In contrast, the N016968 trial, which compared bolus 5-FU/LV to a combination of capecitabine and oxaliplatin (XELOX) showed that elderly patients received a benefit in a short term endpoint of 3-year DFS, long term data from the N016968 trial remain pending.
14 A pooled analysis of 12,669 patients from 6 randomizedtrialsevaluatedtheimpactofageontheefficacy of recently tested regimens (oxaliplatin-based, irinotecan-based,andoral fluoropyrimidine-based).
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Seventeen percent of the patients (n = 2170) were $70 years of age. Newer adjuvant therapies were notassociatedwithasignificanttreatmentbenefitin patients $70 compared to those ,70years(Table1). Thiswasconsistentwhenspecificallyevaluatingtrials involving oxaliplatin and trials containing oral fluoropyrimidines.Therewasnoincreaseindeathsin thefirst6monthsofadjuvanttherapybetweenexper-imental and control arms overall or among different types of therapy. The results of this analysis raise concern about the use of oxaliplatin-based regimens in unselected elderly patients.
ASEER-Medicarebasedstudyalsoevaluatedthe use of several regimens in 8,294 patients .65 years receiving adjuvant therapy for stage III colon cancer. 18 The analysis included patients treated with 5-FU/LValone(n=7,726),oxaliplatin-basedtherapy (n = 816), and irinotecan-based therapy (n = 382). After adjusting for multiple factors, oxaliplatin-based therapy was associated with improved overall survival(HR:0.566;95%CI:0.370-0.866;P =0.0087) and colorectal cancer-specific survival (HR: 0.385; 95% CI: 0.208-0.712; P = 0.0023) when compared to 5-FU/LV alone. Neither OS, nor colorectal cancer specific survival differed between irinotecan regimensand5-FU/LValone.Itmustberecognized that population-based studies are subject to potential selection bias as in general healthier patients are more likely to receive the more aggressive treatment.
The decision whether to treat elderly patients with oxaliplatin-based adjuvant therapy will become a growing problem over the next two decades, when the amount of people in the population over age 65 is expected to increase dramatically. This will result in greater numbers of patients requiring adjuvant therapy for resected colorectal cancer, and thus the role of oxaliplatin-based therapy in this situation needs to be furtherdefined.Conflictingresultsoftheabovestudies gives us the opportunity to individualize therapy forpatients.Afitpatientover65withlowcomorbid-ity may be a candidate of oxaliplatin-based adjuvant therapy. However, elderly patients with a poorer performance status and/or comorbidities may be more appropriatefor5-FU/LVorcapecitabinealone.
Therapy for advanced/metastatic disease
In contrast to the adjuvant setting, multiple studies consistently show oxaliplatin-based therapy improves outcomesfortheelderlywithmCRC. [19] [20] [21] [22] Data from these and other trials also demonstrate that toxicities and tolerability were similar between older and younger patients. 16, 23 Thereasonswhythebenefitof oxaliplatin therapy for elderly patients with advanced disease is not as evident in the adjuvant setting are unknown.
Strategies can be applied to reduce or minimize toxicityfromthecommonlyusedFOLFOXregimen. For instance, the "modified" FOLFOX regimens often omit the 5-FU bolus to minimize side effects, especially the degree of neutropenia and mucositis.
Another option is to use the "stop-and-go" strategy as in the OPTIMOX trials. 24 With disease stability, 6-8 cycles of FOLFOX (with or without bevacizumab) can be followed by maintenance 5-FU or capecitabine (and bevacizumab). Upon progression oxaliplatin can be reintroduced or an alternative, irinotecan-based regimen can be used. This strategy does not compromise efficacy, and reduces the incidence of grade 3/4 neurotoxicity, and potentially maximizesbenefitfromoxaliplatintherapy.
Capecitabineplusoxaliplatin(XELOX)wasfound to be non-inferior to 5-FU plus oxaliplatin in a large randomized phase III trial in terms of progressionfree and overall survival. 25 To determine whether this regimen was appropriate for elderly patients, an analysisofaphaseIItrialexaminedoutcomesofwhen XELOXwasusedinpatients$65withmCRC. 22 Of 96 patients on the trial, 44 were $65 years. Older patients received a median of 8 cycles of XELOX. Responserates(RR)(58%and52%),timetotumor progression (TTP) and OS were similar between youngerandolderpatients(P .0.5),andtherewere no significant differences in toxicity. A separate phaseIItrialevaluatingXELOXintheelderlywith mCRCalsoconcludeditwasasafeandeffectiveregimen to use in selected elderly patients. 26 Irinotecan-basedtherapyhasalsobecomeastandardformCRC,typicallywhencombinedwith5-FU/ LV(FOLFIRI).TwophaseIIItrialshaveinvestigated thecombinationofFOLFIRIcomparedto5-FU/LV, andbothdemonstratedimprovedRRandPFSforthe triple combination regimen. 27, 28 The trial by Douillard et al 27 reportedanimprovedOS17.4monthsforthe irinotecan containing regimen versus 14.1 months forthe5-FU/LVarm(P =0.031).Köhneetal 28 did notreportasignificantincreaseinOSforthetriple combinationregimenwhencomparedtothe5-FU/LV arm, but this was felt due to the increased availability of second and third line therapies. Patients over the ageof70appeartoachievesimilarbenefitsaswellas similar toxicity rates as younger individuals receiving irinotecan-based therapy. 29 Triple drug regimens have been examined in advancedCRC.Falconeetal 30 reportedasignificant improvement in OS (22.6 months vs. 16.7 months; HR 0.70, P = 0.032) with FOLFOXIRI when compared to FOLFIRI alone. This trial purposely selected patients to exclude elderly and frail individuals. A separate study comparing these 2 regimens included older patients (median age 66; 56% .65years)andpoorerPS(36%ECOGPSof0).
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Compared the Falcone study, the doses were lower, there was no difference in OS, and elderly patients hadsignificantlymoretoxicity.
More recently, monoclonal antibodies directed againsttheepidermalgrowthfactorreceptor(EGFR), cetuximab and panitumumab, have been developed. When used as a single agent in the last line setting or in combination with cytotoxic chemotherapy, the EGFRinhibitorsprovidebenefitinthemetastaticsetting, but not the adjuvant setting. [32] [33] [34] In an analysis of 56 patients age $70years,theefficacyandtolerability appeared similar between younger and older patients. 35 These agents provide no survival advantage to patients with KRAS mutant tumors, and in fact, have the potential to add harm to this subset of patients. 36, 37 Therefore, all colorectal tumors should betestedforKRASmutationstatuspriortoadministeringEFGRinhibitors.
Bevacizumab is another targeted therapy showing benefit in advanced colorectal cancer. [38] [39] [40] However, the use of bevacizumab in elderly patients should be carefully considered. A 1.8 fold increased risk of arterialthromboticevents(ATE)wasseenwiththeuseof bevacizumab in patients .65 years, an effect magnifiedwithapriorhistoryofATEs. 41 Data from the Bevacizumab Regimens: Investigation ofTreatment Effects and Safety (BRiTE) registry confirmed this risk in patients .75 years. 42 Ontheotherhand,elderly patients did not have an increased risk of gastrointestinal bleeding/perforation or hypertension compared with a younger cohort. Elderly patients must be counseled on the increased risk of ATEs, and for those with prior ATE, bevacizumab is contraindicated.
Newer advances in the treatment of mCRC should not be withheld from older patients based on age alone. Multiple studies indicate selected patients $65 years can achieve similar benefits to oxaliplatin-and irinotecan-based therapy as well as targeted therapy without substantial addition in toxicity. One must use caution in those with poorer PSormultiplecomorbidities,asthesepatientsarea different population than those typically enrolled on clinical trials. Fluoropyrimidine therapy alone may be more appropriate for such individuals.
pancreatic cancer
Pancreatic cancer is a disease of older patients. The medianageatdiagnosisintheUnitedStatesis72years, and over 68% of those diagnosed are $65 years of age. 43 This section will discuss systemic therapy for older patients in the adjuvant, locally advanced, and metastatic settings.
Adjuvant therapy
Two agents are currently used for adjuvant therapy afterresectionofpancreaticcancer:5-FUorgemcitabine.TheESPAC-1trialdemonstratedasmall,but significant survival benefit for 5-FU therapy versus those who did not receive chemotherapy, with median survivals of 19.7 months and 14.0 months respectively (HR0.66[95%CI0.52-0.83],P =0.0005). 44 The subsequent CONKO-1 trial demonstrated a significant increaseinPFSandOSforpatientsreceivinggemcitabine versus observation alone. 45 After extended follow-up, the median OS was 22.8 months in the gemcitabine arm and 20.2 months in the observation arm(P =0.005),withestimatedsurvivalat5yearsof 21.0% and 9.0% respectively.
IntheESPAC-3trialpatientswithresectedpancre-atic cancer were randomized to receive bolus 5-FU/ LV (Mayo Clinic regimen) versus gemcitabine.
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The median age of patients on this trial was 63 years (range 31-85 years). Median survival was similar betweenthe5-FU/LVarmandthegemcitabinearm, 23.0monthsand23.6monthsrespectively(P =0.39). Quality of life (QOL) did not differ between the 2 treatment arms, but there were significantly higher rates of adverse events in the 5FU group. 14% of patients had serious AEs in the 5-FU group, with higher rates of grade 3/4 stomatitis, but hematologic toxicities were more common in the gemcitabine arm. Age was not a prognostic factor for survival. Giventhelowerratesofadverseeventswithgemcitabine, it would appear to be a more reasonable option for elderly patients.
Studiesinvestigatingtheuseofconcurrentchemoradiation therapy in the adjuvant setting have yielded conflictingresultsregardingthesurvivalbenefitwith the addition of radiation therapy. [47] [48] [49] [50] Concurrent chemoradiation therapy is often utilized in the adjuvant setting when there is evidence of nodal involvement detected at the time of surgery. The aforementioned studies did not include subset analyses for tolerability or survival outcomes in elderly patients. However, we might be able to extrapolate from data on the use of concurrent chemoradiation therapy in elderly patients with locally advanced, unresectable pancreatic cancer (seebelow).
Locally advanced disease
Concurrent chemoradiation therapy became a standard for locally advanced, unresectable pancreatic cancer after it was shown to improve 1-year survival by 30% over radiation therapy alone. 51 A small retrospective analysis evaluated outcomes of patients undergoing chemoradiation therapy with protracted 5-FU infusion (200 mg/m 2 /day) along with radiationtherapy(50.4Gyin28fractionsover5.5weeks) accordingtoage:,70years(n=39)or$70 years (n = 19). 52 There were no significant differences in severe toxicity, response rates or incidence in treatment discontinuation.MedianOSwasslightlyhigher amongtheolderpatients(11.3months)versusyounger patients (9.5 months), likely a reflection of higher baseline performance status in the older group. This small study provides evidence that selected elderly patients can tolerate concurrent 5-FU-based chemoradiation therapy as well as younger patients.
Miyamoto et al 53 reported a series of 42 patients .75 years of age who received chemoradiation therapyeitherasadjuvantordefinitivetherapyforpancreatic cancer. The study included 3 patients who received both 5-FU and gemcitabine and 2 patients who received capecitabine as radiosensitizer; the remaining 37 patients received 5-FU. The median OS was 8.6 months in the inoperable patients and 20.6 months for those in the adjuvant therapy group, similar to historic controls. Nausea, pain, and failure to thrive were the most common toxicities during treatment. Hospitalization occurred in 8 patients (19%),7patients(18%)hadanemergencyroomvisit, and9patients(21%)didnotcompletetherapy.
Metastatic disease
The pivotal trial reported by Burris et al 54 established the role of gemcitabine for patients with advanced pancreatic cancer. Patients were randomized to receive gemcitabineversus5-FU(administeredat500mg/m 2 over30minuteswithoutLV).Therewasasignificant OSbenefitinthegemcitabinearmwithamediansurvival of 5.6 months compared to 4.4 months in the 5-FUarm(P =0.0025),andthe1-yearsurvivalrate was 18% versus 2%, respectively. While the difference in median survival was not dramatic, patients in the gemcitabine arm had a significant improvement inclinicalbenefits,pre-definedasanimprovementin performance status, opioid requirements and weight loss(23.8%vs.4.8%).
Wecangaininsightontoxicitiesspecificallyinthe elderly with gemcitabine from a small retrospective study of 39 patients $70 years who received gemcitabine 1000 mg/m 2 weeks 1-3 of a 4 week cycle for advanced pancreatic cancer. 55 Fifty-nine percent of patients received 100% of planned dose-intensity. Grade3-4adverseeventsweremostcommonlyneu-tropenia (38%), thrombocytopenia (28%), and anemia(18%).ThemedianPFSwas7monthsandOS was 10 months. The authors concluded that selected elderly patients could receive similar benefits to younger patients.
Multiple agents have been combined with gemcitabine in attempts to improve outcomes for patients with metastatic pancreatic cancer. The only agent that hasdemonstratedasurvivalbenefitiserlotinib.Ina phase III trial, patients were randomized to gemcitabine plus erlotinib versus gemcitabine alone. 56 The OSwas6.24monthsinthecombinationarmversus 5.91 months alone (HR 0.82; 95% CI 0.69-0.99; P =0.038).Efficacyandtoxicitywasnotevaluated byage.However,duetotheminimalsurvivalbenefit, it is generally felt the increase in toxicity and cost does not warrant the routine use of erlotinib, particularly in the elderly population.
Oxaliplatin has also shown activity in metastatic pancreatic cancer in the second-line setting. 57 Extrapolating from experience among elderly patients with colorectal cancer, one would expect that oxaliplatin could safely be administered to patients $65 years. However, the performance status of patients with metastatic pancreatic cancer typically declinesmuchquickerthanmCRC,soextracaution must be used in this setting. The triple drug combination regimen using 5-FU, irinotecan and oxaliplatin ( FOLFIRINOX), albeit highly active, is likely too toxic to be recommended for standard use in elderly patients with pancreatic cancer. 58 
Gastroesophageal cancers
Patients $65 years of age make up 60.9% and 63.6% of esophageal and gastric cancers respectively. For the general population, there is clear evidence that chemotherapy, whether alone or in combination with radiation therapy, improves survival in patients with gastroesophageal cancers over surgery alone. [59] [60] [61] [62] [63] Preoperative, perioperative, and postoperative regimens with or without radiation therapy have been studied. The following discussion addresses each approach as it relates to treating the elderly.
Perioperative therapy for gastric cancer
The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial randomized patients with operable gastric cancer to receive three cycles of ECF (epirubicin, cisplatin, 5-FU) before and after surgery, versus surgery alone. 61 Patients in the chemotherapy arm had a 5-year survival of 36.3% versus 23% in the surgery alone arm, with a HR for death of 0.74 (95% CI 0.59-0.93; P = 0.009).The median age of patients on the trial was 62 years (range 23-85 years), and 20% of patients were .70 years. The survival results were independent of age, with patients .70yearsbenefit-ting as much as those ,70 years. Toxicity was not evaluated based on age. Postoperative complications did not differ between the two groups, but only half of the patients received chemotherapy after resection mainly due to progression/early death, complications, or patient refusal.
Adjuvant therapy for gastric cancer
Despite many clinical trials, there is no clear adjuvant therapy standard for gastric cancer, although meta-analyses have concluded adjuvant therapy does provide benefit. [64] [65] [66] A recent large meta-analysis fromtheGlobalAdvanced/AdjuvantStomachTumor Research International Collaboration (GASTRIC) Group included 17 randomized trials and 3838 patients. 67 The GASTRIC investigators found that adjuvant therapy for gastric cancer was associated withimprovedsurvival(HR0.82,95%CI0.75-0.9, P , 0.001). There appears to be the greatest benefit from 5-FU based therapy, even as monotherapy. Althoughtherewasnotaspecificanalysisrelatedto age,itislikelythatolderpatientsfitenoughforaclinical trial do stand to benefit from adjuvant therapy, even if they are not candidates for combination therapy regimens.
The Intergroup trial 0116 randomized patients to receive adjuvant 5-FU for one cycle followed by chemoradiation followed by 2 more cycles of 5-FU versus surgery alone. 62 Median survival was superior in the experimental arm compared to surgery alone, 36 months and 27 months respectively, P = 0.005. The median age on the trial was 60 years in the treatment arm (range 25-87) and 59 years in the control arm (range23-30).Theeffectsoftreatmentwereindependent of age, however there was no toxicity analysis in relation to age. Hematologic toxicities occurred in 54% of patients and gastrointestinal toxicity in 33% of patients. This trial was criticized because more than half the patients received less than a D1 resection, and it remains uncertain if chemotherapy would have improved survival had adequate resection been performed on every patient. This regimen is not commonlyutilizedoutsideoftheUS.
A large, randomized phase III trial from Japan demonstratedasurvivalbenefitforS-1,anotheroral fluoropyrimidine, over surgery alone.
63 Three-year OSwas80.1%intheS-1armcomparedto70.1%in thesurgeryalonearm(HR0.68,95%CI0.52to0.87; P = 0.003).The most common adverse events with S-1wereanorexia(6.0%),nausea(3.7%),anddiarrhea(3.1%).DuetodifferencesintolerabilityinnonAsianpatients,S-1hasnotbeenutilizedin Western countries.
Preoperative therapy for esophageal cancer
Ingeneral,thetrendhasbeentoutilizepreoperative therapy in locally advanced adenocarcinomas of the esophagus and gastroesophageal junction, based on resultsofseveralphaseIIItrials.
68, 69 The advantage to this approach is therapy prior to surgical resection is more feasible than after resection. In addition, preoperative therapy can downstage the tumor as well as potentially address any micrometastatic disease.
Data would suggest that elderly individuals have the potential to benefit from this approach as much as younger individuals, with slightly more toxicity. Rice et al 70 reported a retrospective study evaluating patients with esophageal cancer $70 years who did(n=35)ordidnot(n=39)receivepreoperative chemoradiotherapy compared to patients ,70 years. The chemotherapy used was most commonly cisplatin/5-FUorataxane.Theefficacyoftherapydid not differ between younger or older patients, with no differencein1-or3-yearsurvival.Olderage(.70) wasnotapredictorinpostoperativemortality.Older patients had greater incidence of perioperative blood transfusions and postoperative atrial arrhythmias.
For those patients who are not candidates for cisplatin/5-FU, carboplatin and paclitaxel are alternative radiosensitizing agents with OS benefit over surgery alone and an acceptabletoxicityprofile,inparticular for patients with squamous cell carcinomas. 71 
Treatment for advanced/metastatic gastroesophageal cancer
A meta-analysis of randomized phase II and III trials in advanced gastric cancer clearly demonstrated chemotherapy improves survival in advanced gastroesophageal cancer. 72 Multiple agents including platinums, fluoropyrimidines, anthracyclines, taxanes, and irinotecan show activity. The trend over the years has gone from single agent to doublet to triplet chemotherapy regimens. As more agents are used concomitantly, survival has improved at the price of increased toxicity.
Three-drug regimens became a new standard basedonthephaseIIItrialV325thatdemonstrateda survivalbenefitoverfordocetaxelandcisplatinplus fluorouracil (DCF) over cisplatin plus 5-FU (CF) alone. 73 PatientsintheDCFarmhadamedianOSof 9.2 months, compared to 8.6 months in the CF arm (P = 0.02). The 2-year survival rate of 18% in the experimental arm established DCF as a new standard. ThesmallimprovementinOScamewithsignificantly higher rates of grade III/IV neutropenia (82% vs. 57%),diarrhea(19%vs.8%),andlethargy(19%vs. 14%). In addition, 50% of patients were taken off therapy due to adverse events or patient refusal. Elderly patients were very underrepresented in this trial, with the median age of participants 55 years. Given the high rates of hematologic toxicities and smallsurvivalbenefit,itremainsunclearifthisregimenwillbetolerableintheelderlypatient.Modified DCFregimens,suchasreportedbyShahetal 74 are associated with reduced rates of neutropenia without compromisingefficacyandmaybemoreappropriate for older adults.
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The goal of the Randomized ECF for adjuvant and locally advanced esophagogastric cancer (REAL-2) study was to establish the non-inferiorityofcapecitabine(X)to5-FU(F)andoxaliplatin (O)tocisplatin(C)whencombinedwithepirubicin (E). 75 Patients were randomized in a 2 by 2 design to receive ECF, ECX, EOF and EOX.The median survival in the four study arms was 9.9 months, 9.9 months, 9.3 months and 11.2 months respectively. This trial established the non-inferiority of capecitabine (to 5-FU) and oxaliplatin (to cisplatin),aresultthathasenhancedtheoptionsavailable. Importantly, the oxaliplatin-containing arms had less neutropenia, alopecia, renal toxicity, and thromboembolism,butgreaterneuropathyanddiarrhea.In contrast to the V325 trial, REAL-2 included older patients;themedianagevariedbetween61and65 among the treatment arms.
Therehavenotbeenprospectivetrialsspecifically evaluating outcomes in the elderly with esophagogastric cancers. However there are two pooled analyses of data from clinical trials examining outcomes in theelderly.Thefirstincludes257patients$70 years from 3 clinical trials.The incidence of grade III/IV toxicities, response rates, and overall survival did not differ significantly between patients $70 years compared to those ,70 years. Another analysis of 367 patients with incurable esophagogastric cancers within8consecutivefirstlinetherapytrialsthrough North Central Cancer Treatment Group (NCCTG) from 1987 to 2006 included 154 patients $65 years of age. 76 Despite having poorer performance status, there was also no difference in median survival or PFSbetweenolderandyoungerpatientsrespectively. In this analysis, there were higher rates of adverse events including grade 3+ leucopenia, stomatitis, fatigueandgrade4vomiting.Inaddition,therewere higher rates of grade 4+eventsintheelderly(40%vs. 28%, P =0.02).
S-1 has shown activity in patients with advanced gastric cancer both as a single agent and in combination with cisplatin or irinotecan among Japanese patients. 63, [77] [78] [79] However, when tested in the Western patients, S-1 combined with cisplatin did not show a survival advantage over 5-FU plus cisplatin. 80 Therefore, S-1hasnotbeenapprovedforuseintheUS.
TheTrastuzumabforGastricCancer(ToGA)trial demonstrated clear benefit of targeted therapy for gastric cancer and established trastuzumab as the new standard for HER2+ disease. 81 Twenty percent ofpatientsonthistrialhadGEjunctiontumors.Trastuzumab,whenaddedto5-FUpluscisplatin,significantlyimprovedmedianOSover5-FUpluscisplatin alone 13.8 months versus 11.1 months respectively (HR0.74;95%CI0.60-0.91;P =0.0046).Therewas no difference in adverse events between the 2 arms, with nausea, vomiting, and neutropenia being the mostcommontoxicities.Cardiacdysfunction(defined as a $10% drop in left ventricular systolic function to ,50%) occurred in 11 of 237 patients (5%) in the trastuzumab arm compared to 2 of 187 patients (1%) with chemotherapy alone, but these changes were clinically asymptomatic. The average age of the patients on trial was approximately 59 years. Age was aprespecifiedsub-groupofpatientsevaluatedforOS, theHRforsurvival0.66(95%CI0.49-0.88),indicatingasignificantbenefitforpatients$60 years of age. Trastuzumabcanbeusedwithoutaddingsignificant toxicity, however careful monitoring for systolic dysfunction is recommended.
Although multiple clinical trials trying to define optimal management for gastroesophageal cancers have left us with unanswered questions, they have also provided evidence for a variety of agents and regimens that have activity in this disease. This gives oncologists the ability to tailor treatment to the particular needs of each elderly patient.
conclusions
The data reviewed in this article provide evidence that elderly patients with gastrointestinal cancers can benefit from systemic therapy. The decision to select patients for particular regimens should not be basedsolelyonagealone.Likewise,agentsthatprolong survival should not automatically be withheld from patients with imperfect performance status or comorbidity. Each individual should be assessed for an appropriate regimen. Most importantly, the decision of how to treat elderly patients must incorporate goals and preferences of the patient after a careful discussionofrisksandbenefits.
Several tools exist that may be utilized to guide treatment decisions for the older patient with cancer such as geriatric assessment scores, comorbidity indices, frailty indices, and prognostic indices for survival. These may help the clinician to better estimate the patient's physical and mental condition to determineif the potentialsurvivalbenefitsareworththe potential toxicity, however they may not be easy to incorporate in a busy clinical practice. Efforts are ongoing to assess shorter screening tools to identify those geriatric patients who may not tolerate standard therapy. 82 Inordertoimproveuponourknowledgeofhow to treat older patients with cancer, these patients should be enrolled in clinical trials with more frequency.Inaddition,thereisaneedforclinicaltrials need to be designed for this patient population. An upcomingIntergroupstudywillevaluateoxaliplatin/ fl uoropyrimidine therapy plus bevacizumab versus fluoropyrimidineplusbevacizumabasfirst-linetherapyinelderlypatientswithmCRC.Thistrialincorporates as a component the prospective validation of a frailty index. Future trials should also be designed to incorporate an assessment of outcomes in relation to age to provide further guidance on whether the regimen is appropriate for elderly patients.
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